secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2023-06-26T23:59:59+00:00
Accession:  0000950170-23-029736
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen Phase 3 ZEPHYRUS-1 trial of pamrevlumab for IPF fails primary endpoint
-------------------------------------------------------------------------------

- Phase 3 ZEPHYRUS-1 did not meet primary endpoint: change in FVC at week 48 (p=0.29); placebo-corrected difference 70 ml.
- Secondary endpoint (disease progression or death) also not met (HR=0.78, 95% CI 0.52-1.15).
- ZEPHYRUS-2 Phase 3 IPF trial will be discontinued based on these results.
- Company plans cost reductions to extend cash runway into 2026; roxadustat commercialization continues.
- Upcoming milestones: DMD data 3Q 2023, pancreatic cancer data 1H 2024, new IND filings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017023029736/0000950170-23-029736-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017023029736/fgen-20230626.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-029736

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer